1
|
Huang RYC, Wang Y, Jhatakia AD, Deng AX, Bee C, Deshpande S, Rangan VS, Bezman N, Gudmundsson O, Chen G. Higher-Order Structure Characterization of NKG2A/CD94 Protein Complex and Anti-NKG2A Antibody Binding Epitopes by Mass Spectrometry-Based Protein Footprinting Strategies. J Am Soc Mass Spectrom 2021; 32:1567-1574. [PMID: 33415981 DOI: 10.1021/jasms.0c00399] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
NK group 2 member A (NKG2A), an immune checkpoint inhibitor, is an emerging therapeutic target in immuno-oncology. NKG2A forms a heterodimer with CD94 on the cell surface of NK and a subset of T cells and recognizes the nonclassical human leukocyte antigen (HLA-E) in humans. Therapeutic blocking antibodies that block the ligation between HLA-E and NKG2A/CD94 have been shown to enhance antitumor immunity in mice and humans. In this study, we illustrate the practical utilities of mass spectrometry (MS)-based protein footprinting in areas from reagent characterization to antibody epitope mapping. Hydrogen/deuterium exchange mass spectrometry (HDX-MS) in the higher-order structure characterization of NKG2A in complex with CD94 provides novel insights into the conformational dynamics of NKG2A/CD94 heterodimer. To fully understand antibody/target interactions, we employed complementary protein footprinting methods, including HDX-MS and fast photochemical oxidation of proteins (FPOP)-MS, to determine the binding epitopes of therapeutic monoclonal antibodies targeting NKG2A. Such a combination approach provides molecular insights into the binding mechanisms of antibodies to NKG2A with high specificity, demonstrating the blockade of NKG2A/HLA-E interaction.
Collapse
Affiliation(s)
- Richard Y-C Huang
- Pharmaceutical Candidate Optimization, Nonclinical Research and Development, Bristol Myers Squibb Company, Princeton, New Jersey United States
| | - Yun Wang
- Pharmaceutical Candidate Optimization, Nonclinical Research and Development, Bristol Myers Squibb Company, Princeton, New Jersey United States
| | - Amy D Jhatakia
- Discovery Biology, Research and Early Development, Bristol Myers Squibb Company, Redwood City, California United States
| | - Andy X Deng
- Discovery Biotherapeutics, Research and Early Development, Bristol Myers Squibb Company, Redwood City, California United States
| | - Christine Bee
- Discovery Biotherapeutics, Research and Early Development, Bristol Myers Squibb Company, Redwood City, California United States
| | - Shrikant Deshpande
- Discovery Biotherapeutics, Research and Early Development, Bristol Myers Squibb Company, Redwood City, California United States
| | - Vangipuram S Rangan
- Discovery Biotherapeutics, Research and Early Development, Bristol Myers Squibb Company, Redwood City, California United States
| | - Natalie Bezman
- Discovery Biology, Research and Early Development, Bristol Myers Squibb Company, Redwood City, California United States
| | - Olafur Gudmundsson
- Pharmaceutical Candidate Optimization, Nonclinical Research and Development, Bristol Myers Squibb Company, Princeton, New Jersey United States
| | - Guodong Chen
- Pharmaceutical Candidate Optimization, Nonclinical Research and Development, Bristol Myers Squibb Company, Princeton, New Jersey United States
| |
Collapse
|
2
|
Chowdari NS, Zhang Y, McDonald I, Johnson W, Langley DR, Sivaprakasam P, Mate R, Huynh T, Kotapati S, Deshpande M, Pan C, Menezes D, Wang Y, Rao C, Sarma G, Warrack BM, Rangan VS, Mei-Chen S, Cardarelli P, Deshpande S, Passmore D, Rampulla R, Mathur A, Borzilleri R, Rajpal A, Vite G, Gangwar S. Design, Synthesis, and Structure-Activity Relationships of Novel Tetrahydroisoquinolino Benzodiazepine Dimer Antitumor Agents and Their Application in Antibody-Drug Conjugates. J Med Chem 2020; 63:13913-13950. [PMID: 33155811 DOI: 10.1021/acs.jmedchem.0c01385] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
A series of tetrahydroisoquinoline-based benzodiazepine dimers were synthesized and tested for in vitro cytotoxicity against a panel of cancer cell lines. Structure-activity relationship investigation of various spacers guided by molecular modeling studies helped to identify compounds with picomolar activity. Payload 17 was conjugated to anti-mesothelin and anti-fucosylated monosialotetrahexosylganglioside (FucGM1) antibodies using lysosome-cleavable valine-citrulline dipeptide linkers via heterogeneous lysine conjugation and bacterial transglutaminase-mediated site-specific conjugation. In vitro, these antibody drug conjugates (ADCs) exhibited significant cytotoxic and target-mediated selectivity on human cancer cell lines. The pharmacokinetics and efficacy of these ADCs were further evaluated in gastric and lung cancer xenograft models in mice. Consistent pharmacokinetic profiles, high target specificity, and robust antitumor activity were observed in these models after a single dose of the ADC-46 (0.02 μmol/kg).
Collapse
Affiliation(s)
- Naidu S Chowdari
- Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States
| | - Yong Zhang
- Bristol Myers Squibb Research & Early Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Ivar McDonald
- Bristol Myers Squibb Research & Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States
| | - Walter Johnson
- Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States
| | - David R Langley
- Bristol Myers Squibb Research & Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States
| | - Prasanna Sivaprakasam
- Bristol Myers Squibb Research & Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States
| | - Robert Mate
- Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States
| | - Tram Huynh
- Bristol Myers Squibb Research & Early Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Srikanth Kotapati
- Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States
| | - Madhura Deshpande
- Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States
| | - Chin Pan
- Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States
| | - Daniel Menezes
- Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States
| | - Yichong Wang
- Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States
| | - Chetana Rao
- Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States
| | - Ganapathy Sarma
- Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States
| | - Bethanne M Warrack
- Bristol Myers Squibb Research & Early Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Vangipuram S Rangan
- Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States
| | - Sung Mei-Chen
- Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States
| | - Pina Cardarelli
- Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States
| | - Shrikant Deshpande
- Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States
| | - David Passmore
- Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States
| | - Richard Rampulla
- Bristol Myers Squibb Research & Early Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Arvind Mathur
- Bristol Myers Squibb Research & Early Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Robert Borzilleri
- Bristol Myers Squibb Research & Early Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Arvind Rajpal
- Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States
| | - Gregory Vite
- Bristol Myers Squibb Research & Early Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Sanjeev Gangwar
- Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States
| |
Collapse
|
3
|
Kotapati S, Passmore D, Yamazoe S, Sanku RKK, Cong Q, Poudel YB, Chowdari NS, Gangwar S, Rao C, Rangan VS, Cardarelli PM, Deshpande S, Strop P, Dollinger G, Rajpal A. Universal Affinity Capture Liquid Chromatography-Mass Spectrometry Assay for Evaluation of Biotransformation of Site-Specific Antibody Drug Conjugates in Preclinical Studies. Anal Chem 2019; 92:2065-2073. [DOI: 10.1021/acs.analchem.9b04572] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
4
|
Nambiar DK, Aguilera T, Cao H, Kwok S, Kong C, Bloomstein J, Wang Z, Rangan VS, Jiang D, von Eyben R, Liang R, Agarwal S, Colevas AD, Korman A, Allen CT, Uppaluri R, Koong AC, Giaccia A, Le QT. Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance. J Clin Invest 2019; 129:5553-5567. [PMID: 31710313 PMCID: PMC6877340 DOI: 10.1172/jci129025] [Citation(s) in RCA: 85] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2019] [Accepted: 09/12/2019] [Indexed: 02/03/2023] Open
Abstract
Immune checkpoint inhibitors (ICIs), although promising, have variable benefit in head and neck cancer (HNC). We noted that tumor galectin-1 (Gal1) levels were inversely correlated with treatment response and survival in patients with HNC who were treated with ICIs. Using multiple HNC mouse models, we show that tumor-secreted Gal1 mediates immune evasion by preventing T cell migration into the tumor. Mechanistically, Gal1 reprograms the tumor endothelium to upregulate cell-surface programmed death ligand 1 (PD-L1) and galectin-9. Using genetic and pharmacological approaches, we show that Gal1 blockade increases intratumoral T cell infiltration, leading to a better response to anti-PD1 therapy with or without radiotherapy. Our study reveals the function of Gal1 in transforming the tumor endothelium into an immune-suppressive barrier and that its inhibition synergizes with ICIs.
Collapse
Affiliation(s)
- Dhanya K. Nambiar
- Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA
| | - Todd Aguilera
- Department of Radiation Oncology, University of Texas Southwestern, Dallas, Texas, USA
| | - Hongbin Cao
- Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA
| | - Shirley Kwok
- Department of Pathology, Stanford University School of Medicine, Stanford, California, USA
| | - Christina Kong
- Department of Pathology, Stanford University School of Medicine, Stanford, California, USA
| | - Joshua Bloomstein
- Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA
| | - Zemin Wang
- Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California, USA
| | - Vangipuram S. Rangan
- Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California, USA
| | - Dadi Jiang
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Rie von Eyben
- Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA
| | - Rachel Liang
- Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA
| | - Sonya Agarwal
- Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA
| | - A. Dimitrios Colevas
- Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
| | - Alan Korman
- Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California, USA
| | - Clint T. Allen
- Translational Tumor Immunology Program, National Institute on Deafness and Other Communication Disorders (NIDCD), Bethesda, Maryland, USA
| | - Ravindra Uppaluri
- Department of Surgery – Otolaryngology, Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, USA
| | - Albert C. Koong
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Amato Giaccia
- Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA
| | - Quynh Thu Le
- Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA
| |
Collapse
|
5
|
Chowdari NS, Pan C, Rao C, Langley DR, Sivaprakasam P, Sufi B, Derwin D, Wang Y, Kwok E, Passmore D, Rangan VS, Deshpande S, Cardarelli P, Vite G, Gangwar S. Uncialamycin as a novel payload for antibody drug conjugate (ADC) based targeted cancer therapy. Bioorg Med Chem Lett 2019; 29:466-470. [DOI: 10.1016/j.bmcl.2018.12.021] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2018] [Revised: 12/01/2018] [Accepted: 12/10/2018] [Indexed: 11/27/2022]
|
6
|
Ponath P, Menezes D, Pan C, Chen B, Oyasu M, Strachan D, LeBlanc H, Sun H, Wang XT, Rangan VS, Deshpande S, Cristea S, Park KS, Sage J, Cardarelli PM. A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent In Vitro and In Vivo Antitumor Activity in Preclinical Models of Small Cell Lung Cancer. Clin Cancer Res 2018; 24:5178-5189. [PMID: 30021910 DOI: 10.1158/1078-0432.ccr-18-0018] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2018] [Revised: 03/15/2018] [Accepted: 07/11/2018] [Indexed: 12/30/2022]
Abstract
Purpose: The ganglioside fucosyl-GM1 (FucGM1) is a tumor-associated antigen expressed in a large percentage of human small cell lung cancer (SCLC) tumors, but absent in most normal adult tissues, making it a promising target in immuno-oncology. This study was undertaken to evaluate the preclinical efficacy of BMS-986012, a novel, nonfucosylated, fully human IgG1 antibody that binds specifically to FucGM1.Experimental Design: The antitumor activity of BMS-986012 was evaluated in in vitro assays using SCLC cells and in mouse xenograft and syngeneic tumor models, with and without chemotherapeutic agents and checkpoint inhibitors.Results: BMS-986012 showed a high binding affinity for FcγRIIIa (CD16), which resulted in enhanced antibody-dependent cellular cytotoxicity (ADCC) against FucGM1-expressing tumor cell lines. BMS-986012-mediated tumor cell killing was also observed in complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP) assays. In several mouse SCLC models, BMS-986012 demonstrated efficacy and was well tolerated. In the DMS79 xenograft model, tumor regression was achieved with BMS-986012 doses of 0.3 mg/kg and greater; antitumor activity was enhanced when BMS-986012 was combined with standard-of-care cisplatin or etoposide. In a syngeneic model, tumors derived from a genetically engineered model of SCLC were treated with BMS-986012 or anti-FucGM1 with a mouse IgG2a Fc and their responses evaluated; when BMS-986012 was combined with anti-PD-1 or anti-CD137 antibody, therapeutic responses significantly improved.Conclusions: Single-agent BMS-986012 demonstrated robust antitumor activity, with the addition of chemotherapeutic or immunomodulatory agents further inhibiting SCLC growth in the same models. These preclinical data supported evaluation of BMS-986012 in a phase I clinical trial of patients with relapsed, refractory SCLC. Clin Cancer Res; 24(20); 5178-89. ©2018 AACR.
Collapse
Affiliation(s)
- Paul Ponath
- Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California
| | - Daniel Menezes
- Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California
| | - Chin Pan
- Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California
| | - Bing Chen
- Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California
| | - Miho Oyasu
- Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California
| | - Debbie Strachan
- Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California
| | - Heidi LeBlanc
- Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California
| | | | | | - Vangipuram S Rangan
- Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California
| | - Shrikant Deshpande
- Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California
| | - Sandra Cristea
- Departments of Pediatrics and Genetics, Stanford University School of Medicine, Stanford, California
| | - Kwon-Sik Park
- Departments of Pediatrics and Genetics, Stanford University School of Medicine, Stanford, California
| | - Julien Sage
- Departments of Pediatrics and Genetics, Stanford University School of Medicine, Stanford, California
| | - Pina M Cardarelli
- Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California.
| |
Collapse
|
7
|
Liu A, Kozhich A, Passmore D, Gu H, Wong R, Zambito F, Rangan VS, Myler H, Aubry AF, Arnold ME, Wang J. Quantitative bioanalysis of antibody-conjugated payload in monkey plasma using a hybrid immuno-capture LC–MS/MS approach: Assay development, validation, and a case study. J Chromatogr B Analyt Technol Biomed Life Sci 2015; 1002:54-62. [DOI: 10.1016/j.jchromb.2015.08.007] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2015] [Revised: 08/05/2015] [Accepted: 08/06/2015] [Indexed: 10/23/2022]
|
8
|
Wang H, Rangan VS, Sung MC, Passmore D, Kempe T, Wang X, Thevanayagam L, Pan C, Rao C, Srinivasan M, Zhang Q, Gangwar S, Deshpande S, Cardarelli P, Marathe P, Yang Z. Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacokinetics in humans. Biopharm Drug Dispos 2015; 37:93-106. [PMID: 25869904 DOI: 10.1002/bdd.1953] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2015] [Revised: 03/11/2015] [Accepted: 03/31/2015] [Indexed: 11/11/2022]
Abstract
CD70 is a tumor necrosis factor (TNF)-like type II integral membrane protein that is transiently expressed on activated T- and B-lymphocytes. Aberrant expression of CD70 was identified in both solid tumors and haematologic malignancies. BMS-936561 (αCD70_MED-A) is an antibody-drug conjugate composed of a fully human anti-CD70 monoclonal antibody (αCD70) conjugated with a duocarmycin derivative, MED-A, through a maleimide-containing citrulline-valine dipeptide linker. MED-A is a carbamate prodrug that is activated by carboxylesterase to its active form, MED-B, to exert its DNA alkylation activity. In vitro serum stability studies suggested the efficiencies of hydrolyzing the carbamate-protecting group in αCD70_MED-A followed a rank order of mouse>rat > >monkey>dog~human. Pharmacokinetics of αCD70_MED-A was evaluated in mice, monkeys, and dogs after single intravenous doses. In mice, αCD70_MED-A was cleared rapidly, with no detectable exposures after 15 min following dosing. In contrast, αCD70_MED-A was much more stable in monkeys and dogs. The clearance of αCD70_MED-A in monkeys was 58 mL/d/kg, ~2-fold faster than that in dogs (31 mL/d/kg). The human PK profiles of the total αCD70 and αCD70_MED-A were predicted using allometrically scaled monkeys PK parameters of αCD70 and the carbamate hydrolysis rate constant estimated in dogs. Comparing the predicted and observed human PK from the phase I study, the dose-normalized concentration-time profiles of αCD70_MED-A and the total αCD70 were largely within the 5(th)-95(th) percentile of the predicted profiles.
Collapse
Affiliation(s)
- Haiqing Wang
- Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Princeton, NJ, United States
| | - Vangipuram S Rangan
- Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA, United States
| | - Mei-Chen Sung
- Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA, United States
| | - David Passmore
- Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA, United States
| | - Thomas Kempe
- Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA, United States
| | - Xiaoli Wang
- Clinical Pharmacology, Bristol-Myers Squibb, Princeton, NJ, United States
| | - Lourdes Thevanayagam
- Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA, United States
| | - Chin Pan
- Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA, United States
| | - Chetana Rao
- Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA, United States
| | - Mohan Srinivasan
- Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA, United States
| | - Qian Zhang
- Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA, United States
| | - Sanjeev Gangwar
- Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA, United States
| | - Shrikant Deshpande
- Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA, United States
| | - Pina Cardarelli
- Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA, United States
| | - Punit Marathe
- Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Princeton, NJ, United States
| | - Zheng Yang
- Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Princeton, NJ, United States
| |
Collapse
|
9
|
Sankaranarayanan S, Barten DM, Vana L, Devidze N, Yang L, Cadelina G, Hoque N, DeCarr L, Keenan S, Lin A, Cao Y, Snyder B, Zhang B, Nitla M, Hirschfeld G, Barrezueta N, Polson C, Wes P, Rangan VS, Cacace A, Albright CF, Meredith J, Trojanowski JQ, Lee VMY, Brunden KR, Ahlijanian M. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. PLoS One 2015; 10:e0125614. [PMID: 25933020 PMCID: PMC4416899 DOI: 10.1371/journal.pone.0125614] [Citation(s) in RCA: 109] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2015] [Accepted: 03/24/2015] [Indexed: 12/04/2022] Open
Abstract
In Alzheimer’s disease (AD), an extensive accumulation of extracellular amyloid plaques and intraneuronal tau tangles, along with neuronal loss, is evident in distinct brain regions. Staging of tau pathology by postmortem analysis of AD subjects suggests a sequence of initiation and subsequent spread of neurofibrillary tau tangles along defined brain anatomical pathways. Further, the severity of cognitive deficits correlates with the degree and extent of tau pathology. In this study, we demonstrate that phospho-tau (p-tau) antibodies, PHF6 and PHF13, can prevent the induction of tau pathology in primary neuron cultures. The impact of passive immunotherapy on the formation and spread of tau pathology, as well as functional deficits, was subsequently evaluated with these antibodies in two distinct transgenic mouse tauopathy models. The rTg4510 transgenic mouse is characterized by inducible over-expression of P301L mutant tau, and exhibits robust age-dependent brain tau pathology. Systemic treatment with PHF6 and PHF13 from 3 to 6 months of age led to a significant decline in brain and CSF p-tau levels. In a second model, injection of preformed tau fibrils (PFFs) comprised of recombinant tau protein encompassing the microtubule-repeat domains into the cortex and hippocampus of young P301S mutant tau over-expressing mice (PS19) led to robust tau pathology on the ipsilateral side with evidence of spread to distant sites, including the contralateral hippocampus and bilateral entorhinal cortex 4 weeks post-injection. Systemic treatment with PHF13 led to a significant decline in the spread of tau pathology in this model. The reduction in tau species after p-tau antibody treatment was associated with an improvement in novel-object recognition memory test in both models. These studies provide evidence supporting the use of tau immunotherapy as a potential treatment option for AD and other tauopathies.
Collapse
Affiliation(s)
- Sethu Sankaranarayanan
- Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
- * E-mail: (SS); (KB); (MA)
| | - Donna M. Barten
- Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
| | - Laurel Vana
- Center for Neurodegenerative Disease Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
| | - Nino Devidze
- Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
| | - Ling Yang
- Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
| | - Gregory Cadelina
- Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
| | - Nina Hoque
- Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
| | - Lynn DeCarr
- Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
| | - Stefanie Keenan
- Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
| | - Alan Lin
- Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
| | - Yang Cao
- Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
| | - Bradley Snyder
- Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
| | - Bin Zhang
- Center for Neurodegenerative Disease Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
| | - Magdalena Nitla
- Center for Neurodegenerative Disease Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
| | - Gregg Hirschfeld
- Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
| | - Nestor Barrezueta
- Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
| | - Craig Polson
- Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
| | - Paul Wes
- Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
| | - Vangipuram S. Rangan
- Research and Development, Bristol-Myers Squibb, Redwood City, California, United States of America
| | - Angela Cacace
- Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
| | - Charles F. Albright
- Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
| | - Jere Meredith
- Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
| | - John Q. Trojanowski
- Center for Neurodegenerative Disease Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
| | - Virginia M-Y. Lee
- Center for Neurodegenerative Disease Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
| | - Kurt R. Brunden
- Center for Neurodegenerative Disease Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
- * E-mail: (SS); (KB); (MA)
| | - Michael Ahlijanian
- Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
- * E-mail: (SS); (KB); (MA)
| |
Collapse
|
10
|
Zhu L, van de Lavoir MC, Albanese J, Beenhouwer DO, Cardarelli PM, Cuison S, Deng DF, Deshpande S, Diamond JH, Green L, Halk EL, Heyer BS, Kay RM, Kerchner A, Leighton PA, Mather CM, Morrison SL, Nikolov ZL, Passmore DB, Pradas-Monne A, Preston BT, Rangan VS, Shi M, Srinivasan M, White SG, Winters-Digiacinto P, Wong S, Zhou W, Etches RJ. Production of human monoclonal antibody in eggs of chimeric chickens. Nat Biotechnol 2005; 23:1159-69. [PMID: 16127450 DOI: 10.1038/nbt1132] [Citation(s) in RCA: 139] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2005] [Accepted: 07/12/2005] [Indexed: 12/22/2022]
Abstract
The tubular gland of the chicken oviduct is an attractive system for protein expression as large quantities of proteins are deposited in the egg, the production of eggs is easily scalable and good manufacturing practices for therapeutics from eggs have been established. Here we examined the ability of upstream and downstream DNA sequences of ovalbumin, a protein produced exclusively in very high quantities in chicken egg white, to drive tissue-specific expression of human mAb in chicken eggs. To accommodate these large regulatory regions, we established and transfected lines of chicken embryonic stem (cES) cells and formed chimeras that express mAb from cES cell-derived tubular gland cells. Eggs from high-grade chimeras contained up to 3 mg of mAb that possesses enhanced antibody-dependent cellular cytotoxicity (ADCC), nonantigenic glycosylation, acceptable half-life, excellent antigen recognition and good rates of internalization.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal/chemistry
- Blotting, Southern
- Blotting, Western
- CHO Cells
- Calorimetry, Differential Scanning
- Carbohydrates/chemistry
- Chickens
- Cricetinae
- DNA/metabolism
- Egg White
- Embryo, Mammalian/cytology
- Embryo, Nonmammalian
- Enzyme-Linked Immunosorbent Assay
- Female
- Genetic Vectors
- Genome
- Glycosylation
- Humans
- Immunoglobulin G
- Immunohistochemistry
- Isoelectric Focusing
- Mice
- Mice, Inbred BALB C
- Models, Genetic
- Monosaccharides/chemistry
- Oligosaccharides/chemistry
- Ovalbumin/genetics
- Ovalbumin/metabolism
- Polymerase Chain Reaction
- Recombinant Fusion Proteins/chemistry
- Reverse Transcriptase Polymerase Chain Reaction
- Spectrometry, Mass, Electrospray Ionization
- Stem Cells/cytology
Collapse
Affiliation(s)
- Lei Zhu
- Origen Therapeutics, 1450 Rollins Road, Burlingame, California 94010, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Joshi AK, Zhang L, Rangan VS, Smith S. Cloning, expression, and characterization of a human 4'-phosphopantetheinyl transferase with broad substrate specificity. J Biol Chem 2003; 278:33142-9. [PMID: 12815048 DOI: 10.1074/jbc.m305459200] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
A single candidate 4'-phosphopantetheine transferase, identified by BLAST searches of the human genome sequence data base, has been cloned, expressed, and characterized. The human enzyme, which is expressed mainly in the cytosolic compartment in a wide range of tissues, is a 329-residue, monomeric protein. The enzyme is capable of transferring the 4'-phosphopantetheine moiety of coenzyme A to a conserved serine residue in both the acyl carrier protein domain of the human cytosolic multifunctional fatty acid synthase and the acyl carrier protein associated independently with human mitochondria. The human 4'-phosphopantetheine transferase is also capable of phosphopantetheinylation of peptidyl carrier and acyl carrier proteins from prokaryotes. The same human protein also has recently been implicated in phosphopantetheinylation of the alpha-aminoadipate semialdehyde dehydrogenase involved in lysine catabolism (Praphanphoj, V., Sacksteder, K. A., Gould, S. J., Thomas, G. H., and Geraghty, M. T. (2001) Mol. Genet. Metab. 72, 336-342). Thus, in contrast to yeast, which utilizes separate 4'-phosphopantetheine transferases to service each of three different carrier protein substrates, humans appear to utilize a single, broad specificity enzyme for all posttranslational 4'-phosphopantetheinylation reactions.
Collapse
Affiliation(s)
- Anil K Joshi
- Children's Hospital Oakland Research Institute, Oakland, California 94609, USA
| | | | | | | |
Collapse
|
12
|
Abstract
Animal fatty acid synthases are large polypeptides containing seven functional domains that are active only in the dimeric form. Inactivity of the monomeric form has long been attributed to the obligatory participation of domains from both subunits in catalysis of substrate loading and condensation reactions. However, we have engineered a fatty acid synthase containing one wild-type subunit and one subunit compromised by mutations in all seven functional domains that is active in fatty acid synthesis. This finding indicates that a single subunit, in the context of a dimer, is able to catalyze the entire biosynthetic pathway and suggests that, in the natural complex, each of the two subunits forms a scaffold that optimizes the conformation of the companion subunit.
Collapse
Affiliation(s)
- Anil K Joshi
- Children's Hospital Oakland Research Institute, 5700 Martin Luther King Jr. Way, Oakland, CA 94609, USA
| | | | | | | |
Collapse
|
13
|
|
14
|
Abstract
An in vitro mutant complementation approach has been used to map the functional topology of the animal fatty acid synthase. A series of knockout mutants was engineered, each mutant compromised in one of the seven functional domains, and heterodimers generated by hybridizing all possible combinations of the mutated subunits were isolated and characterized. Heterodimers comprised of a subunit containing either a beta-ketoacyl synthase or malonyl/acetyltransferase mutant, paired with a subunit containing mutations in any one of the other five domains, are active in fatty acid synthesis. Heterodimers in which both subunits carry a knockout mutation in either the dehydrase, enoyl reductase, keto reductase, or acyl carrier protein are inactive. Heterodimers comprised of a subunit containing a thioesterase mutation paired with a subunit containing a mutation in either the dehydrase, enoyl reductase, beta-ketoacyl reductase, or acyl carrier protein domains exhibit very low fatty acid synthetic ability. The results are consistent with a model for the fatty acid synthase in which the substrate loading and condensation reactions are catalyzed by cooperation of an acyl carrier protein domain of one subunit with the malonyl/acetyltransferase or beta-ketoacyl synthase domains, respectively, of either subunit. The beta-carbon-processing reactions, responsible for the complete reduction of the beta-ketoacyl moiety following each condensation step, are catalyzed by cooperation of an acyl carrier protein domain with the beta-ketoacyl reductase, dehydrase, and enoyl reductase domains associated exclusively with the same subunit. The chain-terminating reaction is carried out most efficiently by cooperation of an acyl carrier protein domain with the thioesterase domain of the same subunit. These results are discussed in the context of a revised model for the fatty acid synthase.
Collapse
Affiliation(s)
- V S Rangan
- Children's Hospital Oakland Research Institute, 5700 Martin Luther King Jr. Way, Oakland, California 94609, USA
| | | | | |
Collapse
|
15
|
Cohen GB, Rangan VS, Chen BK, Smith S, Baltimore D. The human thioesterase II protein binds to a site on HIV-1 Nef critical for CD4 down-regulation. J Biol Chem 2000; 275:23097-105. [PMID: 10807905 DOI: 10.1074/jbc.m000536200] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
A HIV-1 Nef affinity column was used to purify a 35-kDa Nef-interacting protein from T-cell lysates. The 35-kDa protein was identified by peptide microsequence analysis as the human thioesterase II (hTE) enzyme, an enzyme previously identified in a yeast two-hybrid screen as a potential Nef-interacting protein. Immunofluorescence studies showed that hTE localizes to peroxisomes and that coexpression of Nef and hTE leads to relocalization of Nef to peroxisomes. Interaction of Nef and hTE was abolished by point mutations in Nef at residues Asp(108), Leu(112), Phe(121), Pro(122), and Asp(123). All of these mutations also abrogated the ability of Nef to down-regulate CD4 from the surface of HIV-infected cells. Based on the x-ray and NMR structures of Nef, these residues define a surface on Nef critical for CD4 down-regulation. A subset of these mutations also affected the ability of Nef to down-regulate major histocompatibility complex class I. These results, taken together with previous studies, identify a region on Nef critical for most of its known functions. However, not all Nef alleles bind to hTE with high affinity, so the role of hTE during HIV infection remains uncertain.
Collapse
Affiliation(s)
- G B Cohen
- AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA
| | | | | | | | | |
Collapse
|
16
|
Witkowski A, Joshi AK, Rangan VS, Falick AM, Witkowska HE, Smith S. Dibromopropanone cross-linking of the phosphopantetheine and active-site cysteine thiols of the animal fatty acid synthase can occur both inter- and intrasubunit. Reevaluation of the side-by-side, antiparallel subunit model. J Biol Chem 1999; 274:11557-63. [PMID: 10206962 DOI: 10.1074/jbc.274.17.11557] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The objective of this study was to test a new model for the homodimeric animal FAS which implies that the condensation reaction can be catalyzed by the amino-terminal beta-ketoacyl synthase domain in cooperation with the penultimate carboxyl-terminal acyl carrier protein domain of either subunit. Treatment of animal fatty acid synthase dimers with dibromopropanone generates three new molecular species with decreased electrophoretic mobilities; none of these species are formed by fatty acid synthase mutant dimers lacking either the active-site cysteine of the beta-ketoacyl synthase domain (C161A) or the phosphopantetheine thiol of the acyl carrier protein domain (S2151A). A double affinity-labeling strategy was used to isolate dimers that carried one or both mutations on one or both subunits; the heterodimers were treated with dibromopropanone and analyzed by a combination of sodium dodecyl sulfate/polyacrylamide gel electrophoresis, Western blotting, gel filtration, and matrix-assisted laser desorption mass spectrometry. Thus the two slowest moving of these species, which accounted for 45 and 15% of the total, were identified as doubly and singly cross-linked dimers, respectively, whereas the fastest moving species, which accounted for 35% of the total, was identified as originating from internally cross-linked subunits. These results show that the two polypeptides of the fatty acid synthase are oriented such that head-to-tail contacts are formed both between and within subunits, and provide the first structural evidence in support of the new model.
Collapse
Affiliation(s)
- A Witkowski
- Children's Hospital Oakland Research Institute, Oakland, California 94609, USA
| | | | | | | | | | | |
Collapse
|
17
|
Rangan VS, Joshi AK, Smith S. Fatty acid synthase dimers containing catalytically active beta-ketoacyl synthase or malonyl/acetyltransferase domains in only one subunit can support fatty acid synthesis at the acyl carrier protein domains of both subunits. J Biol Chem 1998; 273:34949-53. [PMID: 9857025 DOI: 10.1074/jbc.273.52.34949] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
A double-tagging, dual affinity chromatographic procedure, which permits isolation of dimers independently mutated in each subunit, has been exploited to probe the functional topology of the animal fatty acid synthase. Dimers were engineered in which the chain-terminating thioesterase reaction was compromised by mutation of the (active-site) serine residue in both subunits; these dimers assembled two long-chain fatty acyl moieties, which remained covalently linked to the 4'-phosphopantetheine residues of the two acyl carrier protein domains. Significantly, dimers that contained an additional mutation that compromised the activity of either the beta-ketoacyl synthase or malonyl/acetyltransferase activity in only one subunit also assembled two long-chain acyl moieties. In contrast, in a control experiment, introduction of an additional mutation that compromised the function of the acyl carrier protein domain in only one subunit resulted in the assembly of only one long-chain acyl moiety per dimer. Because the beta-ketoacyl synthase and malonyl/acetyltransferase domains are located near the amino terminus of the polypeptide and the acyl carrier protein domain near the carboxyl terminus, these results support a modified model for the animal fatty acid synthase in which head-to-tail functional contacts are possible both within as well as between subunits.
Collapse
Affiliation(s)
- V S Rangan
- Children's Hospital Oakland Research Institute, Oakland, California 94609, USA
| | | | | |
Collapse
|
18
|
Joshi AK, Rangan VS, Smith S. Differential affinity labeling of the two subunits of the homodimeric animal fatty acid synthase allows isolation of heterodimers consisting of subunits that have been independently modified. J Biol Chem 1998; 273:4937-43. [PMID: 9478938 DOI: 10.1074/jbc.273.9.4937] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
To explore the domain interactions that are required for catalytic activity of the multifunctional, homodimeric fatty acid synthase (FAS), we have formulated a strategy that allows isolation of modified dimers containing independently mutated subunits. Either a hexahistidine or a FLAG octapeptide tag was incorporated into the FAS at either the amino terminus, within an internal noncatalytic domain, or at the carboxyl terminus. The presence of the tags had no effect on the activity of the wild-type FAS. His-tagged dimers were mixed with FLAG-tagged dimers, and the subunits were randomized to produce a mixture of His-tagged homodimers, FLAG-tagged homodimers, and doubly tagged heterodimers. The doubly tagged heterodimers could be purified to homogeneity by chromatography on an anti-FLAG immunoaffinity column followed by a metal ion chelating column. This procedure for isolation of FAS heterodimers was utilized to determine whether the two centers for fatty acid synthesis in the FAS dimer can function independently of each other. Doubly tagged heterodimers, consisting of one wild-type subunit and one subunit in which the thioesterase activity had been eliminated, either by mutation or by treatment with phenylmethanesulfonyl fluoride, have 50% of the wild-type thioesterase activity and, in the presence of substrates, accumulate a long chain fatty acyl moiety on the modified subunit, thus blocking further substrate turnover at this center. Nevertheless, the ability of the heterodimer to synthesize fatty acids is also 50% of the wild-type FAS, demonstrating that an individual center for fatty acid synthesis has the same activity when paired with either a functional or nonfunctional catalytic center.
Collapse
Affiliation(s)
- A K Joshi
- Children's Hospital Oakland Research Institute, Oakland, California 94609, USA
| | | | | |
Collapse
|
19
|
Abstract
Sequence elements have been identified within the 1.2 kb-long first intron of the fatty acid synthase (FAS) gene that mediate both positive and negative effects on transcription. The negative regulatory element, when positioned downstream of either the FAS or simian virus 40 promoter, down-regulates the expression of a coupled reporter gene in an orientation-dependent manner. Sequences mediating this effect have been mapped, by deletion mutagenesis, to two regions approximately within nucleotides +405 to +768 and +924 to +1083. Both regions contain sequence elements that are strongly protected from DNase I digestion by nuclear extracts prepared from liver, but not by those prepared from spleen. The results of run-on assays performed with nuclei derived from tissues that express FAS at either high or low levels indicate that the different rates of transcription of the endogenous FAS gene result from differences in the extent of initiation, so it is unlikely that the negative effect is caused by transcriptional pausing in the first intron. The positive element maps to nt +292 to +297 and corresponds to an authentic binding site for upstream stimulatory factor (USF). This USF-binding element can up-regulate transcription from a heterologous promoter in a position- and orientation-independent manner. However, in the context of the entire FAS first intron, the effect of the USF-binding site is masked unless the effect of the negative elements is ablated by mutagenesis. These results suggest that the dominant negative element of the first intron may play a role in determining the tissue-specific expression of the FAS gene.
Collapse
Affiliation(s)
- B Oskouian
- Children's Hospital Oakland Research Institute, 747 52nd Street, Oakland, CA 94609, USA
| | | | | |
Collapse
|
20
|
Rangan VS, Smith S. Alteration of the substrate specificity of the malonyl-CoA/acetyl-CoA:acyl carrier protein S-acyltransferase domain of the multifunctional fatty acid synthase by mutation of a single arginine residue. J Biol Chem 1997; 272:11975-8. [PMID: 9115261 DOI: 10.1074/jbc.272.18.11975] [Citation(s) in RCA: 52] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
The structural basis for the dual specificity of the malonyl-CoA/acetyl-CoA:acyl carrier protein S-acyltransferase associated with the multifunctional animal fatty acid synthase has been investigated by mutagenesis. Arginine 606, which is positionally conserved in the transacylase domains of all multifunctional fatty acid and polyketide synthases, was replaced by alanine or lysine in the context of the isolated transacylase domain, and the mutant proteins were expressed in Escherichia coli. Malonyl transacylase activity of the Arg-606 --> Ala and Arg-606 --> Lys mutant enzymes was reduced by 100- and 10-fold, respectively. In contrast, acetyl transacylase activity was increased 6.6-fold in the Arg-606 --> Ala mutant and 1.7-fold in the Arg-606 --> Lys mutant. Kinetic studies revealed that selectivity of the enzyme for acetyl-CoA was increased >16,000-fold by the Ala mutation and 16-fold by the Lys mutation. Activity toward medium chain length acyl thioesters was also increased >3 orders of magnitude by mutation of Arg-606, so that the Ala-606 enzyme is an effective medium chain length fatty acyl transacylase. These results indicate that Arg-606 plays an important role in the binding of malonyl moieties to the transacylase domain but is not required for binding of acetyl moieties; these results are also consistent with a mechanism whereby interaction between the positively charged guanidinium group of Arg-606 and the free carboxylate anion of the malonyl moiety serves to position this substrate in the active site of the enzyme.
Collapse
Affiliation(s)
- V S Rangan
- Children's Hospital Oakland Research Institute, Oakland, California 94609, USA
| | | |
Collapse
|
21
|
Rangan VS, Serre L, Witkowska HE, Bari A, Smith S. Characterization of the malonyl-/acetyltransacylase domain of the multifunctional animal fatty acid synthase by expression in Escherichia coli and refolding in vitro. Protein Eng 1997; 10:561-6. [PMID: 9215574 DOI: 10.1093/protein/10.5.561] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
cDNAs of various lengths encoding the second domain of the multifunctional fatty acid synthase (FAS) have been expressed in Escherichia coli and the recombinant proteins refolded in vitro to catalytically active monomeric malonyl-/acetyltransacylases. FAS residues 428-487, previously thought to represent the amino terminus of the malonyl-/acetyltransacylase, can be omitted from the recombinant enzyme with no loss in catalytic activity. This shortened transacylase, consisting of FAS residues 488-809, can be repeatedly denatured and renatured in vitro with reproducibly high recovery and no loss in specific activity. When expressed as a soluble enzyme in Spodoptera frugiperda cells, this transacylase has the same specific activity as the enzyme that has been refolded in vitro. The refolded transacylase consisting of FAS residues 488-809, but not the longer enzyme consisting of residues 428-815, can be crystallized readily. These results suggest that FAS residues 428-487, previously thought to represent the amino terminus of the malonyl-/acetyltransacylase, are not required for catalysis of the transacylase reaction. This region of the FAS is less well conserved than the transacylase catalytic domain and may constitute an extended structural linker that facilitates the functional interaction between the transacylase and acyl carrier protein domains.
Collapse
Affiliation(s)
- V S Rangan
- Children's Hospital Oakland Research Institute, Oakland, CA 94609, USA
| | | | | | | | | |
Collapse
|
22
|
Rangan VS, Smith S. Expression in Escherichia coli and refolding of the malonyl-/acetyltransferase domain of the multifunctional animal fatty acid synthase. J Biol Chem 1996; 271:31749-55. [PMID: 8940200 DOI: 10.1074/jbc.271.49.31749] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
A cDNA encoding residues 429-815 of the multifunctional rat fatty acid synthase has been expressed in Escherichia coli and the recombinant protein refolded in vitro as a catalytically active malonyl-/acetyltransferase. Kinetic properties of the refolded recombinant enzyme were indistinguishable from those of a transferase preparation derived from the natural fatty acid synthase by limited proteolysis, indicating that the transferase domain is capable of folding correctly as an independent protein. Replacement of the active site Ser-581 (full-length fatty acid synthase numbering) with alanine completely eliminated catalytic activity, whereas replacement with cysteine resulted in retention of about 1% activity. The wild type transferase was extremely susceptible to inhibition by diethyl pyrocarbonate, and protection against inhibition was afforded by both malonyl- and acetyl-CoA. Replacement of the highly conserved residue His-683 with Ala reduced activity by 99.95%, and the residual activity was relatively unaffected by diethyl pyrocarbonate. The rate of acylation of the active site serine residue was also reduced by several orders of magnitude in the His-683 --> Ala mutant. These results indicate that His-683 plays an essential role in catalysis, likely by accepting a proton from the active site serine, thus increasing its nucleophilicity.
Collapse
Affiliation(s)
- V S Rangan
- Children's Hospital Oakland Research Institute, Oakland, California 94609, USA.
| | | |
Collapse
|
23
|
Oskouian B, Rangan VS, Smith S. Transcriptional regulation of the rat fatty acid synthase gene: identification and functional analysis of positive and negative effectors of basal transcription. Biochem J 1996; 317 ( Pt 1):257-65. [PMID: 8694772 PMCID: PMC1217471 DOI: 10.1042/bj3170257] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
The gene for fatty acid synthase (FAS), which contains both GC-rich sequences and a TATA box in its promoter region, is expressed in a tissue-specific manner in response to developmental, nutritional and hormonal signals. Here we report the identification of sequence elements in the 5'-flanking region responsible for modulation of basal promoter activity. Transient transfection of H4IIE hepatoma cells and 3T3-30A5 preadipocytes with plasmids containing the chloroamphenicol acetyltransferase gene driven by FAS promoter sequences of different lengths revealed that two regions between nucleotides -249 and -30 contain elements capable of enhancing transcription. One of these positive regulatory elements was localized to nucleotides -241/-236 using DNase I footprinting, electrophoretic mobility-shift assays and mutagenesis. The sequence element is a typical GC box and the nuclear protein binding to this region appears immunochemically indistinguishable from Sp1. The second positive regulatory element, an inverted CCAAT box, was localized to nucleotides -98/-92 by electrophoretic mobility-shift assays and mutagenesis. A putative negative regulatory element, initially identified by reporter gene transfection experiments, was localized between nucleotides -319 and -301 by DNase I footprinting, electrophoretic mobility-shift assays and deletion mutagenesis; this region consists of 78% G residues. In conclusion, initiation of FAS transcription from a single start site is enhanced by the presence of an adjacent TATA motif, an inverted CCAAT box and an upstream binding site for the transcription factor Sp1; further modulation of transcription is achieved through complex interactions between these promoter elements and an upstream negative regulatory element.
Collapse
Affiliation(s)
- B Oskouian
- Children's Hospital Oakland Research Institute, CA 94609-1809, USA
| | | | | |
Collapse
|
24
|
Rangan VS, Oskouian B, Smith S. Identification of an inverted CCAAT box motif in the fatty-acid synthase gene as an essential element for modification of transcriptional regulation by cAMP. J Biol Chem 1996; 271:2307-12. [PMID: 8567694 DOI: 10.1074/jbc.271.4.2307] [Citation(s) in RCA: 61] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
The antagonistic effect of cAMP on the insulin-induced expression of fatty acid synthase (FAS) in liver could be mimicked in vitro using H4IIE hepatoma cells, both by measuring the response of the endogenous FAS gene and by assaying expression of transfected reporter genes containing promoter elements of the FAS gene. 5'-Deletion analysis and replacement mutagenesis revealed that an essential element required for cAMP antagonism of the insulin effect is an inverted CCAAT box located between nucleotides -99 and -92. DNase I foot-printing and gel shift analysis revealed that this region can bind a protein present in nuclei of liver and spleen, organs that express high and undetectable levels of FAS, respectively. This protein is not a CCAAT/enhancerbinding protein, C/EBP. Thus, the FAS gene appears unusual in that the sequence element required for transcriptional regulation by cAMP is neither a cAMP response element (CRE) nor a binding site for AP-1, AP-2, or C/EBP. These results suggest that essential to the regulation of FAS transcription by cAMP is the interaction of an inverted CCAAT box motif with a constitutively produced trans-acting factor that either itself undergoes modification in response to cAMP or associated with a protein that is produced or modified by cAMP exposure.
Collapse
Affiliation(s)
- V S Rangan
- Children's Hospital, Oakland Research Institute, California 94609, USA
| | | | | |
Collapse
|
25
|
Rangan VS, Witkowski A, Smith S. Isolation of a functional transferase component from the rat fatty acid synthase by limited trypsinization of the subunit monomer. Formation of a stable functional complex between transferase and acyl carrier protein domains. J Biol Chem 1991; 266:19180-5. [PMID: 1918034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Limited trypsinization of rat fatty acid synthase monomers results in cleavage at sites protected in the native dimer. A 47,000-Da polypeptide containing the transferase component was isolated from the digest and its location in the multifunctional polypeptide established. Both acetyl and malonyl moieties are transferred stoichiometrically from CoA ester to this polypeptide and each can replace the other, confirming that a single common site is utilized in the loading of these substrates onto the fatty acid synthase. Transferase activity of the 47,000-Da polypeptide decreases with increasing acyl donor chain length (malonyl = acetyl greater than butyryl greater than hexanoyl greater than octanoyl). Activity is inhibited by certain thiol-directed reagents, and protection is afforded by substrate suggesting the presence of a sensitive cysteine residue near the substrate binding site. The transferase was also able to utilize as acyl acceptor the Escherichia coli acyl carrier protein and the acyl carrier protein domain of the multifunctional fatty acid synthase. When the fatty acid synthase monomer was trypsinized under milder conditions, the 47,000-Da transferase domain could be isolated in association with the 8,000-Da acyl carrier protein domain. The transferase was capable of translocating substrate moieties from CoA ester donors to the associated acyl carrier protein. The results provide the first direct evidence that, in the head-to-tail oriented fatty acid synthase homodimer, functional communication between the transferase domain located near the end of one polypeptide and the acyl carrier protein domain located at the opposite end of the other polypeptide is facilitated by a stable physical interaction between these domains.
Collapse
Affiliation(s)
- V S Rangan
- Children's Hospital Oakland Research Institute, California 94609
| | | | | |
Collapse
|
26
|
Abstract
The amino acid sequence of the multifunctional fatty-acid synthase has been examined to investigate the exact location of the seven functional domains. Good agreement in predicting the location of interdomain boundaries was obtained using three independent methods. First, the sites of limited proteolytic attack that give rise to relatively stable, large polypeptide fragments were identified; cryptic sites for protease attack at the subunit interface were unmasked by first dissociating the dimer into its component subunits. Second, polypeptide regions exhibiting higher-than-average rates of non-conservative mutation were identified. Third, the sizes of putative functional domains were compared with those of related monofunctional proteins that exhibit similar primary or secondary structure. Residues 1-406 were assigned to the oxoacyl synthase, residues 430-802 to the malonyl/acetyl transferase, residues 1630-1850 to the enoyl reductase, residues 1870-2100 to the oxyreductase, residues 2114-2190 to the acyl-carrier protein and residues 2200-2505 to the thioesterase. The 47-kDa transferase and 8-kDa acyl-carrier-protein domains, which are situated at opposite ends of the multifunctional subunit, were nevertheless isolated from tryptic digests as a non-covalently associated complex. Furthermore, a centrally located domain encompassing residues 1160-1545 was isolated as a nicked dimer. These findings, indicating that interactions between the head-to-tail juxtaposed subunits occur in both the polar and equatorial regions, are consistent with previously derived electron-micrograph images that show subunit contacts in these areas. The data permit refinement of the model for the fatty-acid synthase dimer and suggest that the malonyl/acetyl transferase and oxoacyl synthase of one subunit cooperate with the reductases, acyl carrier protein and thioesterase of the companion subunit in the formation of a center for fatty-acid synthesis.
Collapse
Affiliation(s)
- A Witkowski
- Children's Hospital Oakland Research Institute, CA 94609
| | | | | | | | | |
Collapse
|
27
|
Rangan VS, Das GC. Purification and biochemical characterization of hepatocyte nuclear factor 2 involved in liver-specific transcription of the human alpha 1-antitrypsin gene. J Biol Chem 1990; 265:8874-9. [PMID: 2341408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
The upstream region of the human alpha 1-antitrypsin gene binds liver-specific proteins. Two of these proteins, hepatocyte nuclear factors 1 and 2, are essential for liver-specific transcription of this gene. We report for the first time the purification of hepatocyte nuclear factor 2 from rat liver nuclei. This protein, purified to apparent homogeneity by DNA sequence-specific affinity chromatography, appeared on sodium dodecyl sulfate-polyacrylamide gels as a single polypeptide band of molecular mass of 68 kDa. The polypeptide after extraction from the gel matrix and subsequent renaturation bound specifically to the recognition sequences (-88 to -125) and protected the same region of the promoter against DNase I digestion.
Collapse
Affiliation(s)
- V S Rangan
- Department of Molecular Biology, University of Texas Health Center, Tyler 75710
| | | |
Collapse
|